SCHEMBL23705012

SCHEMBL23705012

COC(=O)c1ccc(C)c(C(C)(C)C#N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.46
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
XDH P47989 1/20 0.44
ALDH1A1 P00352 5/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 4/20 0.41
CYP2C9 P11712 3/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4211041 0.84 NOTUM (0.46) NOTUMRAB9ANPC1CA12CA1
SCHEMBL2192282 0.84 ALDH1A1 (0.49) NOTUMRAB9ANPC1CA12CA1
SCHEMBL4390242 0.84 MAPT (0.51) NOTUMRAB9ANPC1CA12CA1
SCHEMBL23715060 0.83 HSP90AA1 (0.43) ALDH1A1TDP1KDM4EHPGDHSD17B10
SCHEMBL16804165 0.82 NOTUM (0.55) NOTUMRAB9ANPC1CA12CA1
SCHEMBL2772563 0.81 NOTUM (0.64) NOTUMCA12CA1CA2CA7
SCHEMBL25135200 0.77 KDM4E (0.44) NOTUMRAB9ANPC1CA12CA1
SCHEMBL25497536 0.77 ALDH1A1 (0.48) NOTUMRAB9ANPC1CA12CA1
SCHEMBL1756221 0.76 CA1 (0.50) NOTUMRAB9ANPC1CA12CA1
SCHEMBL2478176 0.74 CA1 (0.49) NOTUMCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB NOTUM 3559/4885RAB9A 572/4885NPC1 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.